Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Santiago Perez-Lloret

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Expert Opinion on Investigational Drugs|January 13, 2016
Investigational drugs for autonomic dysfunction in Parkinson's diseaseSantiago Perez-Lloret
Expert Review of Neurotherapeutics|July 5, 2011
Pramipexole for the treatment of early Parkinson's diseaseSantiago Perez-Lloret, Santiago Perez Lloret, María Verónica Rey, et al.
Expert Opinion on Drug Safety|April 2, 2011
Safety of rasagiline for the treatment of Parkinson's diseaseSantiago Perez-Lloret, Olivier Rascol
CNS Drugs|October 12, 2010
Dopamine receptor agonists for the treatment of early or advanced Parkinson's diseaseSantiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy|July 31, 2010
Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's diseaseSantiago Perez Lloret, Olivier Rascol
Expert Review of Neurotherapeutics|February 6, 2016
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's diseaseSantiago Perez-Lloret, Olivier Rascol
CNS Drugs|June 27, 2016
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson DiseaseSantiago Perez-Lloret, Olivier Rascol
Nature Reviews. Neurology|June 6, 2012
Parkinson disease: Serotonin reuptake inhibitors for depression in PDSantiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy|February 26, 2009
Rotigotine transdermal delivery for the treatment of Parkinson's diseaseOlivier Rascol, Santiago Perez-Lloret
Journal of Neural Transmission (Vienna, Austria : 1996)|March 8, 2018
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesiaSantiago Perez-Lloret, Olivier Rascol
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Expert Opinion on Investigational Drugs|January 13, 2016
Investigational drugs for autonomic dysfunction in Parkinson's diseaseSantiago Perez-Lloret
Expert Review of Neurotherapeutics|July 5, 2011
Pramipexole for the treatment of early Parkinson's diseaseSantiago Perez-Lloret, Santiago Perez Lloret, María Verónica Rey, et al.
Expert Opinion on Drug Safety|April 2, 2011
Safety of rasagiline for the treatment of Parkinson's diseaseSantiago Perez-Lloret, Olivier Rascol
CNS Drugs|October 12, 2010
Dopamine receptor agonists for the treatment of early or advanced Parkinson's diseaseSantiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy|July 31, 2010
Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's diseaseSantiago Perez Lloret, Olivier Rascol
Expert Review of Neurotherapeutics|February 6, 2016
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's diseaseSantiago Perez-Lloret, Olivier Rascol
CNS Drugs|June 27, 2016
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson DiseaseSantiago Perez-Lloret, Olivier Rascol
Nature Reviews. Neurology|June 6, 2012
Parkinson disease: Serotonin reuptake inhibitors for depression in PDSantiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy|February 26, 2009
Rotigotine transdermal delivery for the treatment of Parkinson's diseaseOlivier Rascol, Santiago Perez-Lloret
Journal of Neural Transmission (Vienna, Austria : 1996)|March 8, 2018
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesiaSantiago Perez-Lloret, Olivier Rascol
Pageof 12